| 2.77 -0.14 (-4.81%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.88 |
1-year : | 4.3 |
| Resists | First : | 3.32 |
Second : | 3.69 |
| Pivot price | 3.29 |
|||
| Supports | First : | 2.74 |
Second : | 2.28 |
| MAs | MA(5) : | 3.04 |
MA(20) : | 3.31 |
| MA(100) : | 3.31  |
MA(250) : | 2.25 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.6 |
D(3) : | 11.2 |
| RSI | RSI(14): 28.6 |
|||
| 52-week | High : | 4.17 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ESPR ] has closed below the lower bollinger band by 6.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 17.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.96 - 2.98 | 2.98 - 2.99 |
| Low: | 2.7 - 2.72 | 2.72 - 2.74 |
| Close: | 2.74 - 2.77 | 2.77 - 2.8 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Thu, 05 Mar 2026
Royce & Associates LP Takes Position in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Wed, 04 Mar 2026
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Wed, 04 Mar 2026
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Yahoo Finance UK
Tue, 03 Mar 2026
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1% - Should You Sell? - MarketBeat
Tue, 03 Mar 2026
Esperion Therapeutics (NASDAQ:ESPR) Given New $5.00 Price Target at Needham & Company LLC - MarketBeat
Tue, 03 Mar 2026
Esperion Acquires Enbumyst Maker Corstasis - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 239 (M) |
| Shares Float | 223 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 65.4 (%) |
| Shares Short | 33,450 (K) |
| Shares Short P.Month | 33,930 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.21 |
| Profit Margin | -34.9 % |
| Operating Margin | -11.5 % |
| Return on Assets (ttm) | -5.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 69 % |
| Gross Profit (p.s.) | 0.55 |
| Sales Per Share | 1.27 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -93 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -5.13 |
| PEG Ratio | 0 |
| Price to Book value | -1.26 |
| Price to Sales | 2.17 |
| Price to Cash Flow | -7.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|